CA2777899C - Composition for inhalation comprising a pharmaceutically acceptable glassy matrix - Google Patents

Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Download PDF

Info

Publication number
CA2777899C
CA2777899C CA2777899A CA2777899A CA2777899C CA 2777899 C CA2777899 C CA 2777899C CA 2777899 A CA2777899 A CA 2777899A CA 2777899 A CA2777899 A CA 2777899A CA 2777899 C CA2777899 C CA 2777899C
Authority
CA
Canada
Prior art keywords
composition
metal ion
calcium lactate
ion salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2777899A
Other languages
English (en)
French (fr)
Other versions
CA2777899A1 (en
Inventor
Glen Martyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovata Ltd
Original Assignee
Innovata Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovata Ltd filed Critical Innovata Ltd
Publication of CA2777899A1 publication Critical patent/CA2777899A1/en
Application granted granted Critical
Publication of CA2777899C publication Critical patent/CA2777899C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2777899A 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Active CA2777899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918450.8A GB0918450D0 (en) 2009-10-21 2009-10-21 Composition
GB0918450.8 2009-10-21
PCT/GB2010/001955 WO2011048379A2 (en) 2009-10-21 2010-10-21 Composition

Publications (2)

Publication Number Publication Date
CA2777899A1 CA2777899A1 (en) 2011-04-28
CA2777899C true CA2777899C (en) 2016-03-29

Family

ID=41426476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777899A Active CA2777899C (en) 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix

Country Status (7)

Country Link
US (1) US20130004542A1 (enExample)
EP (1) EP2490670B1 (enExample)
JP (1) JP2013508344A (enExample)
CN (1) CN102665684A (enExample)
CA (1) CA2777899C (enExample)
GB (1) GB0918450D0 (enExample)
WO (1) WO2011048379A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007769A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
UA115989C2 (uk) * 2012-07-05 2018-01-25 Арвен Айлак Санайі Ве Тіджарет А.С. Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
AU2013368298B2 (en) * 2012-12-27 2016-08-11 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
CN104885172B (zh) * 2012-12-27 2019-12-13 3M创新有限公司 电化学装置及其制造方法
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
JP2015116367A (ja) * 2013-12-19 2015-06-25 重人 下山 寝具装置、寝具装置制御方法及びプログラム
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
WO2017100656A1 (en) * 2015-12-11 2017-06-15 Otitopic Inc. Dry powder formulations of aspirin for inhalation
AU2019207288A1 (en) * 2018-01-11 2020-08-13 Emphysema Solutions Bv Compositions and methods for the treatment of lung emphysema and other forms of COPD
GB201817861D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
US20250049862A1 (en) * 2021-12-16 2025-02-13 Alveolus Bio, Inc. Spray dried inhalable biotherapeutics for the treatment of disease
CN115046816B (zh) * 2022-03-11 2025-09-26 桂林优利特医疗电子有限公司 一种尿液有形成分分析仪用结晶质控物的制备方法
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8802174D0 (en) 1988-02-01 1988-03-02 Quadrant Bioresources Ltd Method of drying macromolecules
AU5414990A (en) 1989-04-12 1990-11-05 Aberdeen University Slow release vitreous systems
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0563455A1 (en) 1992-03-31 1993-10-06 Purac Biochem B.V. Particulate solid products containing a lump forming inhibitor
EP0611567B1 (en) * 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP3095624B2 (ja) 1994-07-19 2000-10-10 株式会社ボッシュオートモーティブシステム 積層型熱交換器の偏平チューブのろう付け方法
DE69531992T2 (de) 1994-08-04 2004-07-22 Elan Drug Delivery Ltd., Ruddington Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
JP4502406B2 (ja) 1995-06-07 2010-07-14 クアドラント、ドラッグ、デリバリー、リミテッド 乾燥発泡ガラスマトリックス内に物質を安定に配合する方法及びそれによって得られた組成物
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9621825D0 (en) 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
AU2945199A (en) 1998-03-18 1999-10-11 Ronai, Peter Amorphous glasses for stabilising sensitive products
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2003062074A (ja) * 2001-08-29 2003-03-04 Tomohiko Hashiba 吸入装置
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1480996A1 (en) * 2002-02-04 2004-12-01 Glaxo Group Limited Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
WO2003079993A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
JP2005060330A (ja) * 2003-08-18 2005-03-10 Tomohiko Hashiba 球状タンパク質粉体とその製造方法
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
MX354829B (es) * 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
AU2010229730A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Also Published As

Publication number Publication date
GB0918450D0 (en) 2009-12-09
WO2011048379A2 (en) 2011-04-28
CA2777899A1 (en) 2011-04-28
WO2011048379A3 (en) 2012-01-05
EP2490670A2 (en) 2012-08-29
JP2013508344A (ja) 2013-03-07
CN102665684A (zh) 2012-09-12
US20130004542A1 (en) 2013-01-03
EP2490670B1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
EP2490670B1 (en) Composition for inhalation
EP2429497B1 (en) Process for preparing microparticles
US9011923B2 (en) Suspension formulations
Newman Dry powder inhalers for optimal drug delivery
ES2650663T3 (es) Proceso y producto para inhalación que comprende glicopirrolato
US9907754B2 (en) Taurine compositions suitable for inhalation
JP5318119B2 (ja) 吸入器
JP2011523861A (ja) 吸入器
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
JP5833824B2 (ja) 吸入器
US11672929B2 (en) Product delivery devices and methods
JP2005519095A (ja) 新規製剤
CN111481550A (zh) 含有噻托溴铵和阿福特罗的药物制剂
AU2020356243B2 (en) Novel carrier particles for dry powder formulations for inhalation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140320

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205